BiondVax Pharmaceuticals (NASDAQ:BVXV) Shares Cross Below 50-Day Moving Average of $2.55

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXVGet Rating)’s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.55 and traded as low as $2.13. BiondVax Pharmaceuticals shares last traded at $2.18, with a volume of 19,627 shares trading hands.

Analysts Set New Price Targets

Separately, began coverage on BiondVax Pharmaceuticals in a research note on Thursday, February 9th. They set a “hold” rating on the stock.

BiondVax Pharmaceuticals Stock Performance

The firm has a market capitalization of $4.08 million, a P/E ratio of -0.54 and a beta of 2.49. The stock has a fifty day simple moving average of $2.55 and a two-hundred day simple moving average of $6.17. The company has a debt-to-equity ratio of 5.92, a current ratio of 5.76 and a quick ratio of 5.76.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. increased its stake in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXVGet Rating) by 226.8% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 163,423 shares of the company’s stock after purchasing an additional 113,418 shares during the period. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 as of its most recent SEC filing.

BiondVax Pharmaceuticals Company Profile

(Get Rating)

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza.

Recommended Stories

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with's FREE daily email newsletter.